ELI LILLY AND COMPANY
Eli Lilly and Company ELI LILLY AND COMPANY FILES A FORM 8-K INDIANAPOLIS, January 8, 2019 -Eli Lilly and Company (NYSE / Euronext Paris / SIX: LLY)today informs its shareholders that it has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission ("SEC") on January 7, 2019 announcingthe acquisition of Loxo Oncology.
Lilly makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after Lilly electronically files these documents with, or furnishes them to, the SEC. These documents are posted on Lilly's website at www.lilly.com- under "Investors." The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at www.sec.gov. Copies of the above referenced information will also be made available, free of charge, upon written request to the Company's secretary atLilly Corporate Center, Indianapolis, Indiana 46285, U.S.A.
Regulatory filing PDF file Document title: Eli Lilly and Company files 8-K Document: http://n.eqs.com/c/fncls.ssp?u=OBJBGJXVQQ |
| Language: | English |
| Company: | Eli Lilly and Company |
| Lilly Corporate Center | |
| 46285 Indianapolis | |
| United States | |
| Phone: | +1-317-276-2000 |
| E-mail: | hern_kevin_r@lilly.com |
| Internet: | https://www.lilly.com/ |
| ISIN: | US5324571083 |
| Euronext Ticker: | LLY |
| AMF Category: | Activity of the issuer(acquisitions, sales...) |
| End of Announcement | EQS News Service |
764253 08-Jan-2019 CET/CEST
